Pharma Skeletons By And Featuring Martin Shkreli
Big Pharma is in a bit of a turmoil. One of their own rank, Martin Shkreli. has turned to whistleblowing.
Source: arstechnica
I've never heard of this guy before reading an article Pharma companies disown Shkreli; Pissed, Shkreli airs their dirty laundry.
Apparently he was accused of pumping the drugs prices way over the top of the clouds. He responded by putting up a web page called Pharma Skeletons.
On it Martin lists Big Pharma companies and business, oops, medical their achievements.
Let's quote some hot stuff from this site:
Bayer - We raise prices on drugs by 100%+ but no one notices
Allergan pretends 10% price increases make sense in a no-inflation environment. Just assume no one can do math. A big price increase on a small product is worse than small increases on big products, right?
Remember that this is the company that does not do any R&D -- they buy-in and call that "open science". Open bullshit. No 'lab coats' here.
Biogen - Tecfidera was a cheap drug available overseas.
New drug costs $750,000 its first year and ~$300,000 every year thereafter. Daraprim is $25,000 one time. Get mad!
GlaxoSmithKline - Do we even do pharma anymore? Consumer head now runs our business.
Mallinckrodt / Questcor - Really? Acthar's 65,000% price increase represents your values but Turing doesn't?
And the list goes on and on ...
He includes links, too. Enough of reading material to keep you busy in horror and disbelief.
Big Pharma Owns Our Health And Profits From Keeping Us On The Drugs - Constantly!
My Personal Take
I believe the guy. He is a weasel, apparently a pissed off weasel, but he just might be speaking the truth.
What Do You Think?
More reading on Steemit:
- CONFESSIONS of a BIG PHARMA (Rx) DRUG PUSHER - Gwen Olsen's Story! by @steemtruth
- Big Pharma Shaking as Trump Appoints Top Vaccine Truth Advocate by @lukewearechange
Better and better!
This post has been ranked within the top 80 most undervalued posts in the second half of Feb 05. We estimate that this post is undervalued by $5.90 as compared to a scenario in which every voter had an equal say.
See the full rankings and details in The Daily Tribune: Feb 05 - Part II. You can also read about some of our methodology, data analysis and technical details in our initial post.
If you are the author and would prefer not to receive these comments, simply reply "Stop" to this comment.